Trial · NCT00696241
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696241, Phase 3, Completed, Takeda; results first posted 2011-04-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension. Trials, record NCT00696241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00696241
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
- NCT number
- NCT00696241
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,275 participants, actual
- Lead sponsor
- Takeda
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil and olmesartan, Azilsartan medoxomil and olmesartan, Azilsartan medoxomil and olmesartan, Olmesartan, Placebo
- First posted
- 2008-06-12
- Last updated
- 2011-07-29
- Results first posted
- 2011-04-19
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. |
| Secondary | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Baseline and Week 6. | The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. |
| Secondary | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. |
| Secondary | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | Baseline and Week 6. | The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. |
| Secondary | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. |
| Secondary | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. |
| Secondary | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. |
| Secondary | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. |
| Secondary | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | Baseline and Week 6. | The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. |
| Secondary | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | Baseline and Week 6. | The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | Baseline and Week 6. | Full analysis set with last observation carried forward. | mmHg | LEAST_SQUARES_MEAN |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 outcomesResults by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Azilsartan Medoxomil 20 mg QD | -12.15 | Standard Error 0.709 | mmHg | |
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Azilsartan Medoxomil 40 mg QD | -13.48 | Standard Error 0.704 | mmHg | |
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Azilsartan Medoxomil 80 mg QD | -14.62 | Standard Error 0.706 | mmHg | |
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Olmesartan 40 mg QD | -12.56 | Standard Error 0.696 | mmHg | |
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Placebo QD | -1.40 | Standard Error 1.004 | mmHg | |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Azilsartan Medoxomil 20 mg QD | -14.28 | Standard Error 0.956 | mmHg | |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Azilsartan Medoxomil 40 mg QD | -14.47 | Standard Error 0.952 | mmHg | |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Azilsartan Medoxomil 80 mg QD | -17.58 | Standard Error 0.947 | mmHg | |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Olmesartan 40 mg QD | -14.87 | Standard Error 0.945 | mmHg | |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure | Placebo QD | -2.06 | Standard Error 1.337 | mmHg |
1 to 10 of 75Source ClinicalTrials.gov
See all 75 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Azilsartan Medoxomil 20 mg QD | 283 | |
| Overall Study | STARTED | Azilsartan Medoxomil 40 mg QD | 283 | |
| Overall Study | STARTED | Azilsartan Medoxomil 80 mg QD | 285 | |
| Overall Study | STARTED | Olmesartan 40 mg QD | 282 | |
| Overall Study | STARTED | Placebo QD | 142 | |
| Overall Study | COMPLETED | Azilsartan Medoxomil 20 mg QD | 259 | |
| Overall Study | COMPLETED | Azilsartan Medoxomil 40 mg QD | 261 | |
| Overall Study | COMPLETED | Azilsartan Medoxomil 80 mg QD | 261 | |
| Overall Study | COMPLETED | Olmesartan 40 mg QD | 268 | |
| Overall Study | COMPLETED | Placebo QD | 130 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events95
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Azilsartan Medoxomil 20 mg QD | 13 | 283 | |
| other | Headache | Nervous system disorders | Azilsartan Medoxomil 40 mg QD | 9 | 281 | |
| other | Headache | Nervous system disorders | Azilsartan Medoxomil 80 mg QD | 16 | 284 | |
| other | Headache | Nervous system disorders | Olmesartan 40 mg QD | 9 | 282 | |
| other | Headache | Nervous system disorders | Placebo QD | 10 | 142 | |
| other | Dyslipidemia | Metabolism and nutrition disorders | Azilsartan Medoxomil 20 mg QD | 10 | 283 | |
| other | Dyslipidemia | Metabolism and nutrition disorders | Azilsartan Medoxomil 40 mg QD | 11 | 281 | |
| other | Dyslipidemia | Metabolism and nutrition disorders | Azilsartan Medoxomil 80 mg QD | 16 | 284 | |
| other | Dyslipidemia | Metabolism and nutrition disorders | Olmesartan 40 mg QD | 10 | 282 | |
| other | Dyslipidemia | Metabolism and nutrition disorders | Placebo QD | 3 | 142 |
1 to 10 of 95Source ClinicalTrials.gov
See all 95 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Azilsartan Medoxomil 20 mg QD | ||
| Total, all-cause mortality | Azilsartan Medoxomil 40 mg QD | ||
| Total, all-cause mortality | Azilsartan Medoxomil 80 mg QD | ||
| Total, all-cause mortality | Olmesartan 40 mg QD | ||
| Total, all-cause mortality | Placebo QD | ||
| Total, other adverse events | Azilsartan Medoxomil 20 mg QD | 23 | 283 |
| Total, other adverse events | Azilsartan Medoxomil 40 mg QD | 19 | 281 |
| Total, other adverse events | Azilsartan Medoxomil 80 mg QD | 32 | 284 |
| Total, other adverse events | Olmesartan 40 mg QD | 18 | 282 |
| Total, other adverse events | Placebo QD | 13 | 142 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00696241
GET https://conductscience.org/api/trials/v1/NCT00696241/results?page=2